News

Targeting ‘Neurodegenerative Disease’, GENUV’s New Drug Development St...

Targeting ‘Neurodegenerative Disease’, GENUV’s New Drug Development Strategy   Building a Neural Stem Cell-Based Neuro-regenerative New Drug Screening Platform and Next Generation Transgenic Mous...

BioSpectator

Genuv Unveils GNUV205, a Bifunctional Fusion Protein That Potently Reg...

SEOUL, Republic of Korea & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genuv Inc., a clinical-stage biotechnology company focused on innovative drug discovery for degenerative central nervous system diseases and advanced immu...

BusinessWire

[2019 Korea Patent Award] GENUV ... Developing Treatments for Neurodeg...

[2019 Korea Patent Award] GENUV ... Developing Treatments for Neurodegenerative Diseases with ATRIVIEW™ Technology     GENUV was honored with "2019 Korea Patent Award'.   We have focuse on b...

Hankook Daily Newspaper

GENUV CEO Sung-Ho Han, "To make real progress in the treatment of ALS ...

Maeil Economics

GENUV, Receives Approval for ALS Phase 1·2a Clinical Studies on New Dr...

MoneyToday

GENUV, Receives Approval for ALS Phase 1·2a Clinical Studies on New Dr...

YoungDoctors

GENUV, Receives Approval for ALS Phase 1·2a Clinical Studies

Maeil Economics

GENUV, To drive growth by finding partner for new drug development

GENUV (former, Shine Biopharma) attended "2018 BIO USA" and the exerpt translation of the relevant article is as below.     "To drive growth by finding partner for new drug development,” K&n...

Seoul Economic Daily